A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention, and is devoted to eliminating cancer in Texas, the nation, and the world.
Houston, Texas Clinical Trial Location
University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd,
Houston, TX 77030